Biotech · Private company
Beacon Therapeutics
Track this companyFree. Adds Beacon Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials105 recruiting or active
Pipeline programs11From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline11
- ControlPhase 3 · X-Linked Retinitis PigmentosaClinicalTrials.gov · fetched Nov 12, 2026
- rAAV2tYF-GRK1-hRPGRcoPhase 3 · X-Linked Retinitis PigmentosaClinicalTrials.gov · fetched Nov 12, 2026
- Adeno-associated virus vector expressing a human RPGR genePhase 2 · X-Linked Retinitis Pigmentosa (XLRP)ClinicalTrials.gov · fetched Nov 12, 2026
- AGTC-402Phase 2 · AchromatopsiaClinicalTrials.gov · fetched Nov 12, 2026
- AGTC-501 (high dose and modified corticosteroid regimen)Phase 2 · X-Linked Retinitis PigmentosaClinicalTrials.gov · fetched Nov 12, 2026
- AGTC-501 (high dose and standard corticosteroid regimen)Phase 2 · X-Linked Retinitis PigmentosaClinicalTrials.gov · fetched Nov 12, 2026
- AGTC-501 (low dose and standard corticosteroid regimen)Phase 2 · X-Linked Retinitis PigmentosaClinicalTrials.gov · fetched Nov 12, 2026
- rAAV1-CB-hAATPhase 2 · Alpha-1 Antitrypsin DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- rAAV2tYF-CB-hRS1Phase 2 · X-linked RetinoschisisClinicalTrials.gov · fetched Nov 12, 2026
- rAAV2tYF-GRK1-RPGRPhase 2 · X-Linked Retinitis PigmentosaClinicalTrials.gov · fetched Nov 12, 2026
- rAAV2tYF-PR1.7-hCNGB3Phase 2 · AchromatopsiaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis PigmentosaPHASE2 · ACTIVE_NOT_RECRUITING · started Sep 10, 2025ClinicalTrials.gov NCT07174726 · fetched Nov 12, 2026
- A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRPPHASE2_PHASE3 · ACTIVE_NOT_RECRUITING · started Mar 14, 2024ClinicalTrials.gov NCT04850118 · fetched Nov 12, 2026
- A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)PHASE2 · ENROLLING_BY_INVITATION · started Nov 14, 2023ClinicalTrials.gov NCT06275620 · fetched Nov 12, 2026
- A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)PHASE2 · ACTIVE_NOT_RECRUITING · started Apr 13, 2021ClinicalTrials.gov NCT06333249 · fetched Nov 12, 2026
- Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR MutationsPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Apr 16, 2018ClinicalTrials.gov NCT03316560 · fetched Nov 12, 2026
- Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)COMPLETED · started Dec 1, 2017ClinicalTrials.gov NCT03314207 · fetched Nov 12, 2026
- Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)PHASE1_PHASE2 · UNKNOWN · started Aug 3, 2017ClinicalTrials.gov NCT02935517 · fetched Nov 12, 2026
- Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial)PHASE1_PHASE2 · UNKNOWN · started Apr 11, 2016ClinicalTrials.gov NCT02599922 · fetched Nov 12, 2026
- Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)PHASE1_PHASE2 · COMPLETED · started May 1, 2015ClinicalTrials.gov NCT02416622 · fetched Nov 12, 2026
- Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin DeficiencyPHASE2 · COMPLETED · started Jun 1, 2010ClinicalTrials.gov NCT01054339 · fetched Nov 12, 2026